Our goal is to study neuroprotection methods and improve prehospital organization and acute revascularization treatment leading to better life after stroke. Our research group build on a strong and well-established cross-disciplinary collaboration.

My lab aims to understand how and when Parkinson’s disease begins. We employ advanced multi-modal imaging studies of patient cohorts including PET, SPECT & MRI, histology studies of patient brain and gut tissues, and mechanistic studies in experimental animal models.

We study pituitary hormones and diseases with a special focus on growth hormone (GH). We focus on effects of GH and insulin on substrate metabolism and insulin sensitivity. We do studies in patients with acromegaly and GH-deficiency, pituitary-adrenal axis disorders and gluocorticoid excess.

We are interested in the somatosensory nervous system and the pathophysiology and therapy of neuropathic pain. We focus on translational and clinical research including mechanism-based clinical trials.
See also Danish Pain Research Centre

We trace uncertainties of prognostics and decision making in unresponsive patients with serious brain injury between scientific and clinical reasoning. Studying knowledge relationality in an interdisciplinary team with outset in anthropology and medical humanities. See also: bit.ly/3cxUyiL.

We use biophysical modelling and MRI to develop techniques to study the structure of the brain on a micrometer scale. Our work enables subtle changes in microstructure of the living brain to be visualized noninvasively, with applications for e.g. earlier diagnostics of neurodegenerative diseases.

I research the brain bases of musical behavior, specifically skilled performance, and interpersonal coordination. Applications span music education, human-machine interaction, and the evaluation of clinical conditions that impair movement fluency and social functioning.

We investigate changes in cells and molecules primarily in the central and peripheral nervous system. We use cultured cells, transgenic animal models and samples from patients combined with methods from advanced light and electron microscopy, molecular biology, genetics and stereology.

The research goal of my team is to use different types of brain scans and other advanced neuroimaging techniques to understand the brain changes occurring in Parkinson’s and other neurodegenerative diseases. We aim to identify targets for new therapeutic strategies, including neuromodulation surgery.

We combine epidemiological basic science with research in assessment, diagnostics and new treatment programmes to develop rational strategies for prevention and treatment of functional disorders in children and adolescents. A key issue is to translate our findings into clinical practice.

I work as a stroke physician at Department of Neurology at Aarhus University Hospital. My research interest is mainly on prehospital triage of patients with acute stroke. Also, I am interested in peri-procedual management of endovascular therapy.

My research group works on the mechanisms of ALS, polyneuropathy and criticial illness myopathy, and earlier diagnosis of these using novel methods. We are pionering the development and implementation of cortical excitability testing with TMS, muscle/nerve excitability testing and MScanFit MUNE.

Main Research is clinical interventions for ADHD, OCD and Tourette Syndrome, and research in outreach programmes. Both non-pharmacological interventions for children with ADHD, cognitive behavioural therapy for OCD and Tourette's Syndrome as well as add-on projects on neuropsychological aspects and genetics are in focus.

We study mechanisms in the neurobiology of mental health disorders, in particular Gut-Brain interactions, the role of food components, atypical neurotransmitters, and rapid-acting drugs. We examine behaviour, in vivo neurochemistry, molecular/cellular biology, and morphology in advanced models.

Our research focuses on the investigation of pathogenic processes in Parkinson’s disease (PD) using experimental animal models and human patient tissue. We employ histology, behavioral testing of PD rodent models, PET/MRI imaging and tracer studies to evaluate disease progression.

I investigate the brain mechanisms involved in memory for music and temporal sequences. My research utilises MEG and MRI to examine the dynamics of both automatic and conscious memory as well as predictive processes. In addition, I study how aging and musical training influence these brain dynamics.

Can we improve rehabilitation for people with acquired brain injuries? My research focuses on technology-assisted rehabilitaion, specifically Brain Computer Interfaces to restore upper limb function after stroke. Furthermore, I work with digital behavior as a means of health monitoring.

Our research group is interested in identifying risk factors related to the development of persistent symptoms after acute whiplash trauma and understanding the mechanisms within the biopsychosocial model in the recovery. We include questionnaires, clinical examinations, and register data.

My research partly focuses on cognitive impairment in primarily neurodegenerative diseases and partly on the highly interdisciplinary field of human-technology interaction. The latter spans from Internet-delivered intervention research to basic research into social cognition and implicit biases in relation to interactions with social robots.

We investigate blood-brain signalling with a focus on acute stroke and the neurovascular coupling using molecular tools and advanced imaging techniques. This includes studies of molecular changes in acute stroke, neuroprotective molecules, and how systemic signals affect the neurovascular coupling.

My research focus on all aspects of eating disorders (binge eating disorders, anorexia and bulimia nervosa) but especially assessment, diagnostics, treatment outcome, involuntary treatment including clinical and register based studies.

My research is focused on depression and novel treatment strategies. My studies are translational including animal models of depression and human samples – integrating behavioral, molecular, and pharmacological approaches. The main goals are better treatment and identification of biomarkers.

We develop methods to measure brain changes based on MRI and other imaging modalities that allow us to understand disease processes and quantify their progression in various brain disorders. We have a particular focus on neurodegenerative diseases, such as Alzheimer, Parkinson, and multiple sclerosis.

We study 1) the comorbidity between mental disorders and somatic diseases, particularly immune-related diseases and whether inflammation relates to a subgroup of mental disorders, and 2) the effect of different psychopharmacological and anti-inflammatory medications on severe mental disorders.

Smell is a key contributor to flavour of food and social interaction. For the 15% of the population suffering from smell loss, the importance of smell is evident. We aim to create better understanding of smell, why smell loss occurs, and how to treat or alleviate the negative impact of smell loss.

Our aim is to create a wearable seizure alarm for patients with epilepsy. The alarm system is based on heart rate variability measured with wearable electrocardiography (ECG). The seizure alarm will be a vital asset for patients enabling caregivers to take necessary precautions during seizures.

My research focus on clinical applications of music with a specific interest in the use of music as a sleep aid. We use behavioural and neuroimaging methods to study the effects of music on health as well as to understand the mechanisms underlying the impact of music on brain, mind, and body.

Methodology for electrodiagnosis of neuromuscular diseases with special emphasis on diagnostic criteria for amyotrophic lateral sclerosis. The use of quantitative neurophysiological methods including electroencephalographic reactivity for prognostication of comatose patients.

We focus on changes in the peripheral nervous system (PNS), especially on understanding why some patients develop neuropathic pain, aiming to identify novel treatment targets. We use e.g. skin biopsies combined with advanced microscopy, molecular biology, genetics and stereology.

We use PET imaging to study in vivo the biochemical changes in novel rodent and minipig animal models of neuropsychiatric and neurodegenerative disorders. We examine efficacy of putative therapeutics (neuroprotectants, stem cells, brain stimulation) as a prelude to human imaging studies.

My research area is cerebrovascular disease and dementia aiming to identify new strategies to target prevention, and modifying the progression, of cerebrovascular disease, including stroke, and subsequent dementia. We study capillary dysfunction on MRI, diet, genetics, and extracellular vesicles.

Our research focuses on the molecular correlates of treatment response to rapid acting antidepressants with particular emphasis on ketamine and psilocybin. We are also focusing on protein-protein interactions regulating the trafficking and function of the sortilin receptor and the serotonin transporter.

The world around us is full of rhythms: events over time. We study how humans process rhythms by recording neural and behavioral responses. Using non-invasive neuroscientific tools, such as M/EEG or MRI, we explore how neuronal populations synchronize to periodicities of the sensory input to support rhythmic perception and production in music.

Our work concerns the use of Gottingen minipig as a model animal in neurosurgery and neuroscience. In my research, I focus on studying the anatomy and histology of the minipig brain, as well as describing brain tissue reaction in various disease models and after using different treatment modalities.

Our research is driven by a strong interest in understanding how early life environment interacts with (epi)genetic structures, modify cognitive, immune and metabolic development and increases the risk for neuropsychiatric disorders, including addiction, later in life.

Neuromarkers helping in a clinical seeting to estimat neuronal damage are most needed. E.g. neurofilaments are proteins selectively expressed in the cytoskeleton of neurons, and increased levels are a marker of axonal damage. We investigate the role and need in various nerve injuries and diseases.

We are interested in the role of ultrasound in neuromuscular diseases. We investigate the usefulness of ultrasound as a tool to understand nerve/muscle pathology, alongside electrodiagnosis , in entrapments neuropathies, traumatic /inflammatory nervelesions, and amyotrophic lateral sclerosis.

Research fields (aim): Spinal cord injury (reduce the primary and secondary pathophysiological process), the degenerative spine (individualized treatment) and congenital and acquired spinal cord malformations (improve diagnostics and treatment in the pathology and surrounding cerebro-spinal fluid).

The overall aim of our research is to improve our understanding of the molecular mechanisms behind psychiatric disease. We are specifically interested in investigating the relationship between inflammation and depression with a view to develop alternative pharmacological treatment strategies.

We investigate risk factors in early life for neuro- or psychiatric disorders. The ongoing project is on neonatal hyperbilirubinemia and its short and long-term consequences on neurological development. This may contribute to understanding the extent and frequency of Kernicterus Spectrum Disorder.

Our research group conducts basic science and clinical consciousness research. In our current main line of research, we use MRI based to build neuroarchitectural models with the aim of providing exhaustive explanations for a range of phenomena in conscious perception and related cognitive functions.

Neurogenic orthostatic hypotension is a red flag for a significant underlying disease. Our focus is at present on Parkinsons disease, diabetes, and TTR-amyloidosis. We can evaluate peripheral small fibre sensory and autonomic function and monitor the cardiovagal and cardiovascular adrenergic system.

We develop novel biomarkers for PET imaging. A current focus is imaging neuropeptides such as oxytocin and neuropeptide Y for the first time in human. We couple this work with analysis of plasma hormones. We apply these methods to study effects of food and oral contraceptives on brain and behaviour.